Microbiotics and LegoChem Bio Collaborate on Bacteriophage Treatment Research
In an effort to find alternatives to traditional antibiotic treatments, Microbiotics CEO, Dong-Eun Yong, announced a collaborative research agreement with LegoChem Bio. The goal of the partnership is to explore the use of bacteriophage treatment, which has the potential to go beyond current antibiotic therapies.
The two companies have established a strategic research collaboration that will integrate their respective technologies. Through this partnership, they will conduct joint research, including clinical collaboration for pneumonia treatment, research on LegoChemBio’s antibiotic pipeline, and microbiotic bacteriophage combination therapy. Additionally, they will work on discovering new ways to utilize bacteriophages for developing antibiotics and anticancer drugs.
CEO Dong-Eun Yong expressed excitement for the collaboration, stating, “LegoChemBio is a leading ADC company in Korea, with extensive knowledge in new drug development. Through this MOU, we hope to create synergies between our bacteriophage technology and LegoChem’s pipeline.”
LegoChem Bio CEO, Kim Yong-joo, praised Microbiotics as a next-generation biotech company, particularly highlighting Professor Yong Dong-eun’s expertise in bacteriophage research. He looks forward to a new turning point through this collaborative research.
Microbiotics, previously selected as one of the top 5 companies in ‘Steintech Bio Season 1,’ and LegoChem Bio, who has been serving as a mentor to Microbiotics, are now formalizing their relationship through this Memorandum of Understanding.
[Source: Biotimes | Author: Kim Su-jin]
Using bacteriophage treatment, searching for new alternatives that go beyond existing antibiotic treatments
Collaborative research on bacteriophage combination therapy of antibiotics and microbiotics with LegoChem Bio
Dong-Eun Yong, CEO of Microbiotics (left), and Young-Rak Cho, Vice President of LegoChem Biosciences, take a commemorative photo after signing a Memorandum of Understanding at the Microbiotics headquarters office in Gasan-dong, Seoul on the 22nd (Photo = Microbiology)
[바이오타임즈] Microbiotics (CEO Dong-eun Yong) announced on the 22nd that it has signed a research collaboration agreement with LegoChem Bio to find an alternative to using bacteriophage treatment to go beyond the current antibiotic treatment.
The two companies decided to establish a strategic research collaboration relationship that can organically combine different technologies each company has.
Through this collaboration, the two companies will carry out joint research, such as ▲ clinical collaboration for the treatment of pneumonia from microbiotics ▲ joint research on LegoChemBio’s antibiotic pipeline and microbiotic bacteriophage combination therapy ▲ discovering ways to use bacteriophages for new antibiotics and anticancer drugs ▲ a plan to move forward.
Yong Dong-eun, CEO of Microbiotics, said, “LegoChemBio is a representative ADC company in Korea, and a bio company with knowledge in new drug development accumulated over 40 years by a founding member of LG Chem.” It is a company that has solved difficult challenges in the process.” He added, “Through this MOU, we are looking for opportunities to create synergies between our bacteriophage technology and the LegoChem pipeline.”
Kim Yong-joo, CEO of LegoChem Bio, said, “Microbiotics is a next-generation bio company that Professor Yong Dong-eun, who has been conducting detailed research in the field of bacteriophage, has accumulated his knowledge over the years.” We look forward to a new turning point through this collaborative research between the two companies.”
Microbiotics was selected as one of the top 5 companies ‘Steintech Bio Season 1’ last year, and LegoChemBio has been active as a mentor for Microbiotics. Through this Memorandum of Understanding, it will develop into a practical collaborative relationship.
[바이오타임즈=김수진 기자] sjkimcap@biotimes.co.kr
Copyright © Biotimes Unauthorized reproduction and redistribution prohibited
#MicrobioticsLegoChemBio #Collaboration #develop #antibiotics #bacteriophage
